Cover Image
市場調查報告書

全球多發性骨髓瘤治療藥市場

Global Multiple Myeloma Drugs Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 320943
出版日期 內容資訊 英文 115 Pages
訂單完成後即時交付
價格
Back to Top
全球多發性骨髓瘤治療藥市場 Global Multiple Myeloma Drugs Market 2015-2019
出版日期: 2014年12月03日 內容資訊: 英文 115 Pages
簡介

全球多發性骨髓瘤治療藥市場,預計2014年∼2019年以8.50%的年複合成長率擴大。

本報告提供全球多發性骨髓瘤治療藥市場市場相關調查分析、市場規模與成長率、市場趨勢、市場推動要素與課題、市場機會驗證、主要供應商等相關的系統性資訊。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 產品簡介

  • Pomalyst/ Imnovid
  • Revlimid
  • Zometa
  • Doxil/Caelyx
  • Thalomid/ Thalidomide Celgene
  • Kyprolis
  • Mozobil
  • Velcade

第5章 市場調查手法

  • 市場調查流程
  • 調查手法

第6章 簡介

第7章 疾病概要

  • 多發性骨髓瘤的理解
  • 病理學
  • 流行病學
  • 診斷
  • 分期
  • 管理
  • 經濟負擔

第8章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第9章 市場區隔:各給藥途徑

  • 口服
  • 非口服

第10章 市場區隔:各劑型

  • 固體
  • 液體

第11章 區域區隔

第12章 購買標準

第13章 推動市場成長要素

第14章 推動因素與其影響

第15章 市場課題

第16章 推動因素與課題的影響

第17章 市場趨勢

第18章 趨勢與其影響

第19章 開發平台的組合

第20章 業者情勢

  • 競爭模式
  • 市場佔有率分析
  • 其他卓越供應商

第21章 主要供應商分析

  • Celgene
    • 主要資料
    • 產業概要
    • 產業策略
    • 產業區分:各收益
    • 主要資訊
    • SWOT分析
  • Johnson & Johnson
  • Novartis
  • Onyx Pharmaceuticals
  • Sanofi
  • 武田藥品工業

第22章 相關報告

圖表

目錄
Product Code: IRTNTR4753

About Multiple Myeloma

Multiple myeloma is a common cancer that affects the plasma cells, a type of white blood cell. It begins in the plasma cells of bone marrow. The primary function of the plasma cells is to combat infections by producing antibodies, which attack germs after recognizing them. In multiple myeloma these plasma cells become malignant, it causes the production of a defective protein, which grows uncontrollably. This protein moves into the bones and cause tumors. Myeloma occurs when the malignant cells form a tumor. According to the Multiple Myeloma Research Foundation, the disease has been classified into six distinct stages: Pain in bone, vulnerability to infections, increased restlessness, kidney and urination ailments, fatigue, increase in thirst, loss of appetite and loss in weight. The disease can be diagnosed by a series of tests. The initial evaluation consists of a blood test, urine test and a bone marrow biopsy. X-ray, MRI scan, CT- scan and PET scan are other tests to diagnose multiple myeloma. Genomic testing is also carried out to confirm the presence of multiple myeloma in the suspected patients.

TechNavio's analysts forecast the Global Multiple Myeloma Drugs market to grow at a CAGR of 8.50 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Multiple Myeloma Drugs market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic and branded therapies used in the treatment of multiple myeloma.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Multiple Myeloma Drugs market. In addition, the report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Celgene
  • Johnson & Johnson
  • Novartis
  • Onyx Pharmaceuticals
  • Sanofi
  • Takeda Pharmaceutical

Other Prominent Vendors

  • AB Science
  • Abbvie
  • Aeterna Zentaris
  • Amgen
  • Bristol Myers Squibb
  • Cephalon
  • Daiichi Sankyo
  • Genta
  • Merck Sharp and Dohme
  • Oncotherapeutics
  • PharmaMar
  • Teva

Market Driver

  • Presence of Unmet Needs
  • For a full, detailed list, view our report

Market Challenge

  • High Cost of Treatment
  • For a full, detailed list, view our report

Market Trend

  • Growing Public Awareness
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Product Profiles

    • 04.1.1. Pomalyst/ Imnovid
    • 04.1.2. Revlimid
    • 04.1.3. Zometa
    • 04.1.4. Doxil/Caelyx
    • 04.1.5. Thalomid/ Thalidomide Celgene
    • 04.1.6. Kyprolis
    • 04.1.7. Mozobil
    • 04.1.8. Velcade

05. Market Research Methodology

  • 05.1. Market Research Process
  • 05.2. Research Methodology

06. Introduction

07. Disease Overview

  • 07.1. Understanding Multiple Myeloma
  • 07.2. Pathophysiology
  • 07.3. Epidemiology
  • 07.4. Diagnosis
  • 07.5. Staging
  • 07.6. Management
  • 07.7. Economic Burden

08. Market Landscape

  • 08.1. Market Overview
  • 08.2. Market Size and Forecast
  • 08.3. Five Forces Analysis

09. Market Segmentation by Route of Administration

  • 09.1. Oral
  • 09.2. Parenteral

10. Market Segmentation by Dosage Form

  • 10.1. Solid
  • 10.2. Liquid

11. Geographical Segmentation

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Pipeline Portfolio

20. Vendor Landscape

  • 20.1. Competitive Scenario
    • 20.1.1. Key News
    • 20.1.2. Mergers and Acquisitions
  • 20.2. Market Share Analysis 2014
    • 20.2.1. Celgene
    • 20.2.2. Johnson & Johnson
    • 20.2.3. Novartis
    • 20.2.4. Onyx
    • 20.2.5. Sanofi
    • 20.2.6. Takeda Pharmaceutical
  • 20.3. Other and Future Prominent Vendors

21. Key Vendor Analysis

  • 21.1. Celgene
    • 21.1.1. Key Facts
    • 21.1.2. Business Overview
    • 21.1.3. Business Strategy
    • 21.1.4. Business Segmentation by Revenue
    • 21.1.5. Sales by Geography
    • 21.1.6. Key Information
    • 21.1.7. SWOT Analysis
  • 21.2. Johnson & Johnson
    • 21.2.1. Key Facts
    • 21.2.2. Business Overview
    • 21.2.3. Business Segmentation by Revenue 2013
    • 21.2.4. Business Segmentation by Revenue 2012 and 2013
    • 21.2.5. Geographical Segmentation by Revenue 2013
    • 21.2.6. Business Strategy
    • 21.2.7. Recent Developments
    • 21.2.8. SWOT Analysis
  • 21.3. Novartis
    • 21.3.1. Key Facts
    • 21.3.2. Business Description
    • 21.3.3. Business Segmentation
    • 21.3.4. Revenue by Business Segmentation
    • 21.3.5. Revenue Comparison 2012 and 2013
    • 21.3.6. Sales by Geography
    • 21.3.7. Business Strategy
    • 21.3.8. Key Developments
    • 21.3.9. SWOT Analysis
  • 21.4. Onyx Pharmaceuticals
    • 21.4.1. Key Facts
    • 21.4.2. Business Overview
    • 21.4.3. Marketed Products
    • 21.4.4. Geographical Segmentation
    • 21.4.5. Business Strategy
    • 21.4.6. Recent Developments
    • 21.4.7. SWOT Analysis
  • 21.5. Sanofi
    • 21.5.1. Key Facts
    • 21.5.2. Business Overview
    • 21.5.3. Business Segmentation by Revenue 2013
    • 21.5.4. Business Segmentation by Revenue 2012 and 2013
    • 21.5.5. Geographical Segmentation by Revenue 2013
    • 21.5.6. Business Strategy
    • 21.5.7. Key Developments
    • 21.5.8. SWOT Analysis
  • 21.6. Takeda Pharmaceutical
    • 21.6.1. Key Facts
    • 21.6.2. Business Overview
    • 21.6.3. Business Segmentation by Revenue 2013
    • 21.6.4. Business Segmentation by Revenue 2013
    • 21.6.5. Geographical Segmentation by Revenue 2013
    • 21.6.6. Business Strategy
    • 21.6.7. Recent Developments
    • 21.6.8. SWOT Analysis

22. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Pathophysiology of Multiple Myeloma
  • Exhibit 3: Indicators of Multiple Myeloma
  • Exhibit 4: Laboratory Tests to Identify Multiple Myeloma
  • Exhibit 5: Diagnosis of Multiple Myeloma
  • Exhibit 6: Staging of Multiple Myeloma
  • Exhibit 7: Management of Multiple Myeloma
  • Exhibit 8: Induction Therapy Recommendations for the Transplant Eligible Candidates
  • Exhibit 9: Maintenance Therapy for the Candidates with Multiple Myeloma
  • Exhibit 10: Supportive Therapy for the Candidates with Multiple Myeloma
  • Exhibit 11: Estimated Expenditure for the Four Type of Treatment Regimens for Multiple Myeloma in the US
  • Exhibit 12: Snapshot of the Economic Burden of Multiple Myeloma
  • Exhibit 13: Snapshot of Global Multiple Myeloma Drugs Market 2014
  • Exhibit 14: Global Multiple Myeloma Drugs Market 2014-2019 (US$ million)
  • Exhibit 15: Global Multiple Myeloma Drugs Market Segmentation By Route Of Administration
  • Exhibit 16: Global Multiple Myeloma Drugs Market Segmentation by Route of Administration 2014
  • Exhibit 17: Global Multiple Myeloma Drugs Market Segmentation by Dosage Form
  • Exhibit 18: Global Multiple Myeloma Drugs Market Segmentation by Dosage Form 2014
  • Exhibit 19: Global Multiple Myeloma Drugs Market by Geographical Segmentation 2014
  • Exhibit 20: Buying Criteria of Global Multiple Myeloma Drugs Market 2014
  • Exhibit 21: Growth Drivers of the Global Multiple Myeloma Drugs Market
  • Exhibit 22: Drivers and their Impact on the Key Customer Category of Global Multiple Myeloma Drugs Market 2014
  • Exhibit 23: Drivers and their Impact on the Geographies of Global Multiple Myeloma Drugs Market 2014
  • Exhibit 24: Challenges of the Global Multiple Myeloma Drugs Market
  • Exhibit 25: Trends of the Global Multiple Myeloma Drugs Market
  • Exhibit 26: Phase III Pipeline Molecules for Multiple Myeloma
  • Exhibit 27: Global Multiple Myeloma Drugs Market Share Analysis 2014
  • Exhibit 28: Sales Forecast of Pomalyst 2014-2018 (US$ million)
  • Exhibit 29: YoY Sales Comparison of Revlimid 2007-2013 (US$ million)
  • Exhibit 30: Sales Forecast of Revlimid 2014-2018 (US$ million)
  • Exhibit 31: YoY Sales Comparison of Thalomid 2007-2013 (US$ million)
  • Exhibit 32: Sales Forecast of Thalomid 2014-2018 (US$ million)
  • Exhibit 33: YoY Sales Comparison of Velcade outside the US 2008-2013 (US$ million)
  • Exhibit 34: Sales Comparison of Zometa in the US and ROW 2007-2013 (US$ million)
  • Exhibit 35: Global YoY Sales Comparison of Zometa 2007-2013 (US$ million)
  • Exhibit 36: YoY Sales Comparison of Zometa in the US 2007-2013 (US$ million)
  • Exhibit 37: YoY Sales Comparison of Zometa in ROW 2007-2013 (US$ million)
  • Exhibit 38: Sales Forecast of Kyprolis 2014-2018 (US$ million)
  • Exhibit 39: Global YoY Sales Comparison of Mozobil 2007-2013 (US$ million)
  • Exhibit 40: Global YoY Sales Comparison of Velcade in Japan 2009-2013 (US$ million)
  • Exhibit 41: Sales Forecast of Velcade 2014-2018 (US$ million)
  • Exhibit 42: Celgene: Business Segmentation by Revenue 2011-2013 (US$ million)
  • Exhibit 43: Celgene: Sales by Geography 2013
  • Exhibit 44: Johnson & Johnson: Business Segmentation by Revenue 2013
  • Exhibit 45: Johnson & Johnson: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 46: Johnson & Johnson: Geographical Segmentation by Revenue 2013
  • Exhibit 47: Novartis AG: Business Segmentation
  • Exhibit 48: Novartis AG: Revenue by Business Segmentation 2013
  • Exhibit 49: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 50: Novartis AG: Revenue by Geographical Segmentation 2013
  • Exhibit 51: Onyx Pharmaceuticals: Marketed Products
  • Exhibit 52: Onyx Pharmaceuticals: Geographical Segmentation
  • Exhibit 53: Sanofi: Business Segmentation by Revenue 2013
  • Exhibit 54: Sanofi: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 55: Sanofi: Geographical Segmentation by Revenue 2013
  • Exhibit 56: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013
  • Exhibit 57: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013 (US$ million)
  • Exhibit 58: Takeda Pharmaceuticals: Geographical Segmentation by Revenue 2013
Back to Top